PE20230373A1 - Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo - Google Patents
Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismoInfo
- Publication number
- PE20230373A1 PE20230373A1 PE2022002658A PE2022002658A PE20230373A1 PE 20230373 A1 PE20230373 A1 PE 20230373A1 PE 2022002658 A PE2022002658 A PE 2022002658A PE 2022002658 A PE2022002658 A PE 2022002658A PE 20230373 A1 PE20230373 A1 PE 20230373A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody
- drug conjugate
- inhibits
- induces
- preparation
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 4
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 4
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 206010017758 gastric cancer Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000011549 stomach cancer Diseases 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 230000005754 cellular signaling Effects 0.000 abstract 1
- 239000000562 conjugate Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta referido a un conjugado de anticuerpo-farmaco (ADC) anti-Claudin 18.2 de formula (I), en donde: D es un fragmento de una molecula bioactiva; L es un enlazador; ? es un numero entre 1 y 10; y, A es un anticuerpo o fragmento de union a antigeno del mismo que se une a CLDN18.2 humano. Este conjugado induce la apoptosis de celulas tumorales (especialmente celulas de cancer gastrico); inhibe la proliferacion de celulas tumorales (especialmente celulas de cancer gastrico); induce y/o aumenta la citotoxicidad dependiente de complemento (CDC); induce y/o aumenta la citotoxicidad mediada por celulas dependiente de anticuerpos (ADCC); inhibe la expresion y activacion de CLDN18.2; inhibe la via de senalizacion celular mediada por CLDN18.2. Tambien se relaciona una composicion farmaceutica que comprende el conjugado de anticuerpo-farmaco o la composicion, y el uso de la composicion farmaceutica en la preparacion de un medicamento para prevenir y/o tratar tumores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010410633 | 2020-05-15 | ||
PCT/CN2021/093348 WO2021228141A1 (zh) | 2020-05-15 | 2021-05-12 | 抗体药物缀合物及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20230373A1 true PE20230373A1 (es) | 2023-03-06 |
Family
ID=78525267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022002658A PE20230373A1 (es) | 2020-05-15 | 2021-05-12 | Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230338565A1 (es) |
EP (1) | EP4151235A1 (es) |
JP (2) | JP7407973B2 (es) |
KR (1) | KR20230012000A (es) |
CN (1) | CN115715202A (es) |
AU (1) | AU2021270940A1 (es) |
CA (1) | CA3178406A1 (es) |
CL (1) | CL2022003170A1 (es) |
CO (1) | CO2022016208A2 (es) |
CR (1) | CR20220580A (es) |
DO (1) | DOP2022000251A (es) |
EC (1) | ECSP22089507A (es) |
IL (1) | IL298184A (es) |
MX (1) | MX2022014332A (es) |
PE (1) | PE20230373A1 (es) |
WO (1) | WO2021228141A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4442688A1 (en) * | 2021-12-02 | 2024-10-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Method for preparing drug-linker conjugate |
WO2023143208A1 (zh) * | 2022-01-26 | 2023-08-03 | 苏州宜联生物医药有限公司 | 一种药物连接体偶联物的制备方法 |
WO2024012523A1 (zh) * | 2022-07-14 | 2024-01-18 | 苏州宜联生物医药有限公司 | 抗体药物偶联物及其制备方法和用途 |
WO2024027708A1 (zh) * | 2022-08-02 | 2024-02-08 | 诺纳生物(苏州)有限公司 | Msln抗体药物偶联物 |
WO2024175042A1 (zh) * | 2023-02-24 | 2024-08-29 | 四川科伦博泰生物医药股份有限公司 | 药物偶联物治疗肿瘤疾病的用途及方法 |
WO2024179561A1 (en) * | 2023-03-02 | 2024-09-06 | Multitude Therapeutics Inc. | Antibody-drug conjugates, pharmaceutical compositions and uses thereof |
CN117327182B (zh) * | 2023-09-19 | 2024-06-04 | 上海交通大学医学院附属仁济医院 | Cldn18.2单域抗体探针的制备方法及应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
PT1354034E (pt) | 2000-11-30 | 2008-02-28 | Medarex Inc | Roedores transgénicos transcromossómicos para produção de anticorpos humanos |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
US9056092B2 (en) * | 2011-12-02 | 2015-06-16 | Ethicon, Inc. | Hemostatic bioabsorbable device with polyethylene glycol binder |
WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
KR102236367B1 (ko) | 2013-07-26 | 2021-04-05 | 삼성전자주식회사 | DARPin을 포함하는 이중 특이 키메라 단백질 |
HUE055424T2 (hu) | 2014-03-17 | 2021-11-29 | Mitsubishi Tanabe Pharma Corp | Antitest-fynomer konjugátumok |
JP2019531084A (ja) * | 2016-07-08 | 2019-10-31 | カースゲン セラピューティクス カンパニー リミテッドCarsgen Therapeutics Co., Ltd. | 抗クローディンタンパク質18a2の抗体及びその応用 |
CN113603703A (zh) * | 2017-12-15 | 2021-11-05 | 四川科伦博泰生物医药股份有限公司 | 生物活性物偶联物及其制备方法和用途 |
WO2019149116A1 (zh) * | 2018-01-30 | 2019-08-08 | 四川科伦博泰生物医药股份有限公司 | 制备偶联物的方法 |
WO2019154120A1 (zh) * | 2018-02-11 | 2019-08-15 | 四川科伦博泰生物医药股份有限公司 | 细胞毒性剂及其偶联物、其制备方法及用途 |
CA3087423A1 (en) * | 2018-03-14 | 2019-09-19 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
CN111110862A (zh) * | 2018-11-01 | 2020-05-08 | 上海健信生物医药科技有限公司 | 抗cldn18.2抗体的药物偶联体及其制备方法和用途 |
CN112770723B (zh) * | 2018-07-25 | 2024-08-02 | 阿克罗斯生物科学公司 | Cldn 18.2特异性单克隆抗体及其使用方法 |
US20230192840A1 (en) * | 2018-12-28 | 2023-06-22 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody and use thereof |
-
2021
- 2021-05-12 CN CN202180032620.1A patent/CN115715202A/zh active Pending
- 2021-05-12 AU AU2021270940A patent/AU2021270940A1/en active Pending
- 2021-05-12 PE PE2022002658A patent/PE20230373A1/es unknown
- 2021-05-12 WO PCT/CN2021/093348 patent/WO2021228141A1/zh active Application Filing
- 2021-05-12 IL IL298184A patent/IL298184A/en unknown
- 2021-05-12 CR CR20220580A patent/CR20220580A/es unknown
- 2021-05-12 EP EP21804105.1A patent/EP4151235A1/en active Pending
- 2021-05-12 MX MX2022014332A patent/MX2022014332A/es unknown
- 2021-05-12 US US17/998,772 patent/US20230338565A1/en active Pending
- 2021-05-12 KR KR1020227043736A patent/KR20230012000A/ko unknown
- 2021-05-12 JP JP2022568760A patent/JP7407973B2/ja active Active
- 2021-05-12 CA CA3178406A patent/CA3178406A1/en active Pending
-
2022
- 2022-11-11 CO CONC2022/0016208A patent/CO2022016208A2/es unknown
- 2022-11-14 CL CL2022003170A patent/CL2022003170A1/es unknown
- 2022-11-14 DO DO2022000251A patent/DOP2022000251A/es unknown
- 2022-11-21 EC ECSENADI202289507A patent/ECSP22089507A/es unknown
-
2023
- 2023-12-19 JP JP2023213677A patent/JP2024037960A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2021270940A1 (en) | 2022-12-15 |
US20230338565A1 (en) | 2023-10-26 |
EP4151235A1 (en) | 2023-03-22 |
MX2022014332A (es) | 2022-12-13 |
JP7407973B2 (ja) | 2024-01-04 |
CO2022016208A2 (es) | 2023-02-27 |
ECSP22089507A (es) | 2023-02-28 |
JP2024037960A (ja) | 2024-03-19 |
CN115715202A (zh) | 2023-02-24 |
KR20230012000A (ko) | 2023-01-25 |
CA3178406A1 (en) | 2021-11-18 |
CR20220580A (es) | 2023-04-11 |
CL2022003170A1 (es) | 2023-05-19 |
WO2021228141A1 (zh) | 2021-11-18 |
DOP2022000251A (es) | 2023-04-16 |
JP2023525120A (ja) | 2023-06-14 |
IL298184A (en) | 2023-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20230373A1 (es) | Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo | |
JOP20210289A1 (ar) | مقترنات عقار - جسم مضاد مثبط لـmcl-1 وطرق لاستخدامها | |
PE20191328A1 (es) | Conjugados de farmacos y anticuerpos anti-ccr7 | |
CL2023001076A1 (es) | Anticuerpos monoclonales anti-ccr8 y sus usos. | |
PE20170517A1 (es) | Conjugados de anticuerpo-farmaco-anti-ptk7 | |
PE20221459A1 (es) | Conjugados anticuerpo-farmaco dirigido a claudina 18.2 | |
ECSP088753A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
MX2021010003A (es) | Anticuerpos anti-mertk de alta afinidad y usos de los mismos. | |
PE20170912A1 (es) | Conjugados de anticuerpo-farmaco | |
AR064360A1 (es) | Anticuerpos humanos que se enlazan a cd70 y usos de los mismos | |
AR077241A1 (es) | Metodo de tratamiento del cancer conantagonista dll4 y agente quimioterapeutico | |
MX2023002330A (es) | Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos. | |
JOP20220070A1 (ar) | مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها | |
BR112022008552A2 (pt) | Moléculas de ligação multiespecíficas de scfv de terminal-n | |
FI3773910T3 (fi) | Humanisoituja eturauhasspesifisen membraaniantigeeni (psma) -vasta-aineen ja lääkkeen konjugaatteja | |
PE20240913A1 (es) | Anticuerpos anti-il-2r agonistas y metodos de uso | |
BR112023021665A2 (pt) | Método para tratar um câncer, e, composição | |
ECSP20020949A (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos | |
MX2023011929A (es) | Anticuerpos anti-c-met y conjugados de anticuerpo-farmaco. | |
CO2021017477A2 (es) | Terapia de combinación | |
BR112021016923A2 (pt) | Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits | |
MX2020002266A (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos. | |
CO2022004606A2 (es) | Conjugados de amatoxina y anticuerpo específicos de linfocitos b | |
MX2022015375A (es) | Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer. |